Arrowstreet Capital
COLL icon

Arrowstreet Capital’s Collegium Pharmaceutical COLL Stock Holding History

Arrowstreet Capital’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Sell
621,920
-81,608
-12% -$2.79M 0.01% 821
2026
Q1 		$23.3M Buy
703,528
+159,755
+29% +$6.76M 0.01% 712
2025
Q4 		$25.2M Buy
543,773
+510,060
+1,513% +$21.3M 0.01% 669
2025
Q3 		$1.18M Buy
+33,713
New +$1.17M ﹤0.01% 1560
2024
Q4 		– Sell
-276,731
Closed -$10.7M – 1770
2024
Q3 		$10.7M Buy
276,731
+203,994
+280% +$7.28M 0.01% 729
2024
Q2 		$2.34M Sell
72,737
-205,776
-74% -$7.14M ﹤0.01% 1033
2024
Q1 		$10.8M Buy
278,513
+59,165
+27% +$2.07M 0.01% 661
2023
Q4 		$6.75M Sell
219,348
-211,195
-49% -$5.29M 0.01% 664
2023
Q3 		$9.62M Buy
430,543
+58,339
+16% +$1.33M 0.01% 525
2023
Q2 		$8M Buy
372,204
+59,330
+19% +$1.35M 0.01% 550
2023
Q1 		$7.51M Buy
+312,874
New +$8.3M 0.01% 604

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Arrowstreet Capital's COLL Position: Q2 2026 in Review

Arrowstreet Capital reduced its Collegium Pharmaceutical (COLL) stake by 12% in Q2 2026, selling an estimated $2.79M and leaving 621,920 shares worth $22.5M. The position accounts for 0.01% of the portfolio, ranked #821.

Arrowstreet Capital first reported a position in COLL in Q1 2023 and has held it in 11 quarters since. The position peaked at $25.2M in Q4 2025. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Arrowstreet Capital held 621,920 shares of Collegium Pharmaceutical worth $22.5M as of Q2 2026.
  • Arrowstreet Capital sold 81,608 Collegium Pharmaceutical shares in Q2 2026, an estimated $2.79M.
  • Collegium Pharmaceutical made up 0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #821 holding.
  • Arrowstreet Capital first reported a position in Collegium Pharmaceutical in Q1 2023 and has held it in 11 quarters since.
  • Arrowstreet Capital's Collegium Pharmaceutical position peaked at $25.2M in Q4 2025.
  • 280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.